ReviewJournal of cell communication and signaling2026
Hepatocyte growth factor/c-Met signaling axis in human diseases: Mechanistic insights and therapeutic potential.
Review in Journal of cell communication and signaling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocyte growth factor (HGF) is a multifunctional cytokine that activates the tyrosine kinase activity of its specific receptor, c-Met (mesenchymal-epithelial transition factor). This activation subsequently regulates downstream signaling pathways such as PI3K/Akt and Ras/MEK, ultimately mediating key biological processes including epithelial cell migration, proliferation, morphogenesis, and damaged tissue regeneration. Accumulating evidence indicates that the HGF/c-Met pathway is critical for embryonic development and tissue homeostasis. Dysregulation of this pathway-whether excessive activation or suppression-is closely associated with the pathogenesis of numerous human diseases. This review systematically synthesizes recent research data on the HGF/c-Met pathway and elucidates its disease-related mechanisms: it promotes malignant tumor progression, participates in viral infectious disease pathogenesis, facilitates tissue injury repair, and is implicated in diabetes mellitus and Alzheimer's disease. It further clarifies the pathway's fundamental biological functions, summarizes potential therapeutic strategies targeting this pathway (e.g., c-Met inhibitors, HGF antagonists, and microRNA-mediated regulation), and discusses challenges in clinical translation (e.g., poor target specificity and drug resistance), providing a theoretical reference for subsequent disease-targeted therapy research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.